Fact-checked by Grok 2 weeks ago

Rotavirus

Rotavirus is a genus of double-stranded RNA viruses belonging to the family Reoviridae, most notable as the leading cause of severe, dehydrating gastroenteritis in infants and young children worldwide.^[1] These viruses primarily infect the small intestine, leading to symptoms such as profuse watery diarrhea, vomiting, fever, and abdominal pain that typically last 3 to 8 days.^[2] Nearly all unvaccinated children experience at least one infection by age 5, with the first episode often being the most severe and occurring before 12 months in developing countries.^[3] The virus features a triple-layered capsid structure enclosing 11 segments of double-stranded RNA, which encode six structural proteins—including the outer capsid proteins VP4 (P types) and VP7 (G types)—and six non-structural proteins.^[3] Genetic diversity arises from reassortment, resulting in numerous strains; the G1P^[4] genotype is the most prevalent globally, though others like G2P^[5] and G3P^[4] also circulate.^[1] Rotaviruses are highly stable in the environment, surviving for weeks or months on surfaces and resisting many common disinfectants, which contributes to their widespread transmission.^[1] Transmission occurs primarily through the fecal-oral route, via contaminated hands, objects, food, or water, making rotavirus highly contagious in settings like daycare centers, households, and hospitals.^[2] Infections are more common during cooler months (January to June) in temperate regions, with an incubation period of about 2 days; individuals remain contagious from the onset of symptoms through up to 3 weeks post-recovery.^[2] Globally, as of 2021, rotavirus accounts for over 25 million outpatient visits, about 1.8 million hospitalizations (as of 2019), and approximately 128,000 deaths annually among children under 5 years—the burden having declined substantially from over 500,000 deaths pre-2006 due to vaccination—mostly from dehydration in low-resource settings.^[6]^[7]^[1] Prevention relies on oral vaccines such as Rotarix (a monovalent human strain, given in 2 doses) and RotaTeq (a pentavalent bovine-human reassortant, given in 3 doses), which provide 85% to 98% efficacy against severe disease when administered starting at 6 to 12 weeks of age.^[1] These vaccines have been introduced in over 130 countries, averting an estimated 139,000 deaths from 2006 to 2019, though global coverage stands at about 59%.^[8] Supportive treatment focuses on oral or intravenous rehydration to prevent complications like electrolyte imbalances and metabolic acidosis, as no specific antiviral therapy exists.^[2] Hand hygiene and sanitation reduce spread but are insufficient alone against this resilient pathogen.^[2]

Virology

Classification

Rotavirus is a genus within the family Reoviridae, subfamily Sedoreovirinae, comprising eleven species designated as Rotavirus A–I (RVA–RVI), Rotavirus K (RVK), and Rotavirus L (RVL), with official binomial names such as Rotavirus alphagastroenteritidis for RVA, classified based on antigenic differences in the inner capsid protein VP6 and genetic relatedness of their segmented double-stranded RNA genomes.^[9]^[10] Among these, RVA (group A), RVB (group B), and RVC (group C) are the primary species associated with gastroenteritis in humans, with RVA being the most prevalent cause of severe disease worldwide.^[11] Strains within RVA, the most studied species, are further classified using a binary nomenclature system developed by the Rotavirus Classification Working Group (RCWG), denoting the genotype of the outer capsid glycoprotein VP7 (G type) and the protease-sensitive protein VP4 (P type). Common human RVA strains include G1P^[4], G2P^[5], G3P^[4], G4P^[4], and G9P^[4], which together account for the majority of infections in children.^[4] The RVA genome consists of 11 distinct double-stranded RNA segments encoding six structural and five non-structural proteins, enabling high genetic diversity through reassortment during co-infection, which can generate novel strains capable of zoonotic transmission or immune evasion.^[13] Recent global surveillance post-2020 has documented the emergence of atypical strains, including G12P^[14] and G12P^[4] variants in regions like Africa and Asia, as well as equine-like G3P^[4] reassortants predominant in Europe and other areas, often featuring DS-1-like backbone genes that may influence vaccine effectiveness.^[15]^[16]

Structure and genome

Rotavirus is a non-enveloped virus belonging to the Reoviridae family, featuring a triple-layered capsid with icosahedral symmetry and an overall diameter of approximately 70 nm.^[17] The outermost capsid layer is composed of the glycoprotein VP7, which forms the smooth icosahedral shell, and protruding spikes formed by VP4, which facilitate viral attachment and entry.^[18] Beneath this lies the intermediate layer made of VP6 trimers, which provide structural stability and determine viral subgroup specificity.^[18] The innermost core layer consists of VP2, which forms the scaffold, along with VP1 (the viral RNA-dependent RNA polymerase) and VP3 (the capping enzyme).^[18] The rotavirus genome is segmented and consists of 11 distinct double-stranded RNA (dsRNA) molecules, totaling approximately 18.5 kilobases (kb).^[18] These segments range in size from about 0.7 kb to 3.3 kb and encode a total of 11 to 12 proteins: six structural proteins (VP1–VP4, VP6, and VP7) that form the virion, and five to six non-structural proteins (NSP1–NSP5, with NSP6 present in some strains) involved in replication and assembly.^[18] The genome's segmented nature allows for genetic reassortment during co-infection, contributing to viral diversity.^[17] The robust, triple-layered capsid imparts significant environmental stability to rotavirus, enabling it to persist outside the host for extended periods, such as up to 60 days on surfaces under favorable conditions.^[4] This stability arises from its lack of an envelope and resistance to inactivation by factors like drying, moderate temperatures (up to 50°C for 30 minutes), and certain pH levels, as well as partial resistance to common disinfectants such as alcohols, though it is susceptible to stronger agents like 2% glutaraldehyde or 0.05% benzalkonium chloride.^[19]^[4]

Proteins

Rotavirus encodes six structural proteins that form the triple-layered virion and five or six non-structural proteins that support viral processes within infected cells. The structural proteins include VP1 through VP4, VP6, and VP7, while the non-structural proteins are designated NSP1 through NSP5, with NSP6 present in some strains.^[20]^[21] VP1 is the RNA-dependent RNA polymerase (RdRp) located in the core of the virion, where it facilitates viral genome transcription and replication; it is activated upon interaction with VP2 and exists in approximately 12 copies per particle.^[20] VP2 forms the innermost core shell, comprising 120 copies that determine the overall particle size and organization; it also exhibits RNA-binding activity essential for genome packaging.^[20] VP3, another core protein present in about 12 copies, functions as a capping enzyme with guanylyltransferase and methyltransferase activities, modifying the 5' ends of viral mRNAs to promote stability and translation.^[20] VP4 is the outer capsid spike protein, with 180 copies mediating initial viral attachment to host cell receptors such as sialic acid and integrins; cleavage by trypsin generates VP5* for membrane penetration and VP8* for carbohydrate binding and hemagglutination, and it serves as the P-type neutralization antigen for serotyping.^[20]^[22] VP6 constitutes the intermediate capsid layer, forming 780 trimers with T=13 symmetry and acting as the major inner capsid protein; it is highly immunogenic and defines the group A antigen used in diagnostics and subgroup specificity.^[20] VP7 is the outer capsid glycoprotein, arranged in 780 Ca²⁺-stabilized trimers that contribute to virion stability; it independently elicits neutralizing antibodies and represents the G-type antigen for serotypic classification.^[20]^[23] The non-structural proteins play critical roles in modulating host responses and coordinating viral assembly. NSP1 antagonizes the host interferon response by targeting transcription factors like IRF3 and NF-κB for degradation, while also suppressing apoptosis to favor viral persistence, though it is dispensable for replication in cell culture.^[21] NSP2 binds single-stranded RNA and exhibits nucleoside triphosphatase (NTPase), RNA triphosphatase (RTPase), and nucleoside diphosphate kinase activities; it interacts with VP1, VP2, and NSP5 to form viroplasms, the sites of genome replication and capsid assembly.^[21] NSP3 enhances viral mRNA translation by binding to the 3' consensus sequence and eIF4G, while displacing host poly(A)-binding protein (PABP) to suppress cellular protein synthesis.^[21] NSP4, a multifunctional enterotoxin, acts as an endoplasmic reticulum receptor for double-layered particles during morphogenesis; it disrupts intracellular calcium homeostasis through viroporin activity, leading to diarrhea via interactions with integrins, calmodulin, and the chloride channel TMEM16A, thereby activating secretory pathways in enterocytes.^[21] NSP5, a phosphoprotein, co-localizes with NSP2 in viroplasms to regulate their formation and dynamics through phosphorylation-dependent interactions with VP1, VP2, and viral RNA.^[21] NSP6, encoded by certain strains, binds nucleic acids in a sequence-independent manner and exhibits a high turnover rate, potentially aiding in viral morphogenesis, though its precise role remains unclear.^[21]

Replication

Rotavirus primarily infects differentiated enterocytes in the small intestine, where it replicates within the cytoplasm of host cells.^[17] The replication cycle begins with viral attachment to the host cell surface, mediated by the outer capsid proteins VP4 and VP7, which bind to sialic acid-containing glycans or histo-blood group antigens on enterocyte receptors such as integrins or gangliosides.^[24] Entry occurs via receptor-mediated endocytosis, forming an endocytic vesicle that internalizes the triple-layered virion.^[25] Within the endosome, uncoating is triggered by the acidic pH (around 6.0–6.5) and lysosomal proteases, which cleave VP4 into VP5* and VP8*, destabilizing the outer capsid and releasing the transcriptionally active double-layered particle (DLP) into the cytoplasm; this process also involves a drop in calcium ion concentration that further facilitates disassembly.^[24] The DLP, containing the viral RNA-dependent RNA polymerase (VP1) and capping enzyme (VP3), then initiates primary transcription in the cytoplasm, producing positive-sense single-stranded RNA (mRNA) transcripts from each of the 11 double-stranded RNA (dsRNA) genome segments; these mRNAs are uncapped at the 5' end but acquire a 7-methylguanosine cap via VP3 activity and terminate with a conserved 3' sequence without polyadenylation.^[26] The viral mRNAs are translated into proteins, including non-structural proteins NSP2 and NSP5, which drive the formation of viroplasms—dynamic, membraneless cytoplasmic inclusions that serve as sites for genome replication and virion assembly; NSP2 exhibits RNA-binding and helicase activities to organize the dsRNA segments, while NSP5 promotes phase separation to condense the viroplasm structure.^[17] Within viroplasms, secondary transcription and replication occur: the positive-sense mRNAs act as templates for negative-sense RNA synthesis by VP1, forming new dsRNA genome segments that are concurrently packaged into subviral particles (SVPs) with VP1, VP2, and VP3 to generate DLPs.^[26] Assembly of mature triple-layered virions proceeds in the rough endoplasmic reticulum (ER), where DLPs bud into the ER membrane via interaction with NSP4, a viroplasm-associated glycoprotein that acts as a receptor and induces calcium release to facilitate envelopment; the transient lipid envelope is rapidly lost as VP7 (an ER-resident glycoprotein) and cleaved VP4 trimers are added to form the outer capsid, yielding infectious particles.^[24] Virions accumulate in the ER until release, primarily through cell lysis in non-polarized cells or via vesicular transport and apical secretion in polarized intestinal epithelial cells, completing the intracellular replication cycle in approximately 12 hours.^[25]

Epidemiology

Global distribution and burden

Prior to the widespread introduction of rotavirus vaccines in the mid-2000s, rotavirus was responsible for an estimated 138 million episodes of diarrhea annually among children under 5 years of age worldwide, resulting in 200,000 to 500,000 deaths each year, with the majority occurring in low- and middle-income countries due to limited access to healthcare and rehydration therapy.17749-6/fulltext)^[1] These figures underscored rotavirus as a leading cause of severe dehydrating gastroenteritis in young children, particularly in regions with high poverty rates and suboptimal sanitation.^[27] The advent of oral vaccines such as Rotarix (monovalent, human-derived) and RotaTeq (pentavalent, bovine-human reassortant), licensed in 2006 and 2008 respectively, has markedly reduced the global burden. Post-vaccination trends indicate a 40-80% decline in rotavirus-related hospitalizations among children under 5 years across implemented programs, with median reductions of around 59% in severe cases and 67% in emergency department visits for acute gastroenteritis.^[28]^[29] Despite this progress, an estimated 128,500 to 170,000 deaths still occur annually as of 2021-2025, with the persistent burden concentrated in Africa and Asia where vaccine coverage remains below 50% in many areas, accounting for over 70% of global fatalities.^[30]^[31] By 2025, rotavirus vaccines have averted over 220,000 deaths globally through the distribution of more than 1 billion doses, primarily via national immunization programs.^[32] Rotavirus infections display distinct seasonal variations influenced by climate: in temperate regions of Europe, North America, and parts of Asia, incidence peaks during winter months, aligning with colder and drier conditions that may enhance viral stability and transmission.^[1] In contrast, tropical and subtropical areas in Africa, Southeast Asia, and Latin America experience year-round transmission with less pronounced seasonality, often showing minor increases during cooler, dry seasons.^[33] These patterns contribute to higher year-round vulnerability in equatorial low-income settings.^[34] The World Health Organization's Global Rotavirus Surveillance Network (GRSN), established in 2008, has been instrumental in tracking these trends by collecting data from over 70 countries on rotavirus detection in diarrheal cases among children under 5.^[35] As of 2024, GRSN reports indicate sustained declines in positivity rates post-vaccination in monitored sites, with global rotavirus detection dropping by about 40% in sentinel laboratories, though gaps persist in under-surveilled regions of sub-Saharan Africa and South Asia.^[29] This network's data up to 2024 informs vaccine policy and highlights the need for expanded coverage to further mitigate the disease burden.^[3]

Impact on humans

Rotavirus primarily affects infants and young children, with the highest incidence and severity occurring between 6 and 24 months of age.^[36] Nearly all children experience at least one rotavirus infection by age 5 years, with approximately 95% infected globally during this period.^[1] Infections are rare in adults due to acquired immunity from prior exposures, which typically result in milder or asymptomatic cases.^[37] Morbidity from rotavirus is significantly higher in vulnerable populations, including malnourished children and those with compromised immune systems, such as individuals living with HIV.^[38] In these groups, the virus leads to more severe dehydration, which remains the primary cause of death associated with rotavirus gastroenteritis.^[39] Prior to the introduction of rotavirus vaccines in 2006, the disease imposed substantial economic burdens in the United States, with annual medical costs for hospitalizations and treatments estimated at around $264 million, contributing to a total societal cost exceeding $1 billion when including indirect expenses.^[40] Globally, rotavirus infections result in significant productivity losses, primarily through caregiver absenteeism and time off work to manage affected children, accounting for a notable portion of the overall economic impact in low- and middle-income countries.^[41] Recent challenges include emerging vaccine hesitancy in certain regions following the COVID-19 pandemic, which has contributed to coverage gaps and disruptions in immunization programs starting in 2020.^[42] Additionally, rotavirus vaccines carry a small risk of intussusception, estimated at 1 to 5 excess cases per 100,000 vaccinated infants.^[42]

Impact on animals

Rotavirus infections are widespread among non-human animals, with group A rotaviruses (RVA) being the most prevalent, affecting a variety of mammals such as cattle, pigs, and dogs, as well as birds including poultry.^[43]^[44]^[45] Group C rotaviruses (RVC) are particularly significant in pigs, where they cause enteric disease alongside group A strains, though they also occur in cattle and dogs.^[46]^[47] These infections primarily target young animals, leading to gastroenteritis and highlighting rotaviruses' broad host range across species.^[48] In veterinary medicine, rotaviruses pose a major threat to livestock, especially through neonatal diarrhea in calves and lambs, which results in high morbidity, dehydration, and mortality rates in affected herds.^[49]^[50] In calves, RVA is a primary cause of scours during the first month of life, often compounded by bacterial co-infections, leading to substantial economic losses in the dairy industry estimated at around $100 million annually in the United States due to treatment costs, reduced growth, and animal mortality.^[51] Similarly, in lambs, rotavirus-associated diarrhea emerges between 2 and 14 days of age, contributing to outbreaks in sheep flocks and indirect economic impacts from impaired productivity.^[52]^[53] These losses underscore the need for vaccination and hygiene measures in intensive farming systems.^[48] Zoonotic transmission of rotavirus between animals and humans is rare but documented, often involving reassortant strains that facilitate interspecies jumps. Bovine RVA strains, particularly G6 genotypes common in cattle, have been identified in human cases of diarrhea among children, suggesting direct or indirect transmission from livestock.^[54]^[55] Full-genome analyses of such strains in pediatric patients from regions like Japan and Nicaragua confirm their bovine origin, emphasizing the potential for animal reservoirs to contribute to human rotavirus diversity.^[56]^[57] Recent wildlife surveillance efforts from 2023 to 2025 have expanded understanding of rotavirus ecology, revealing group A strains in bats and rodents as potential reservoirs that could bridge domestic and sylvatic cycles. Studies using next-generation sequencing detected RVA in fecal samples from wild boars, rodents, bats, and birds across diverse ecosystems, indicating widespread circulation and opportunities for reassortment.^[58] In particular, bat-derived RVA strains with G3P^[59] genotypes have been linked to human infections in children, supporting interspecies transmission from wildlife.^[60] These findings highlight the importance of monitoring non-domestic hosts to assess emerging zoonotic risks.^[61]

Transmission and pathogenesis

Modes of transmission

Rotavirus is primarily transmitted through the fecal-oral route, where infectious particles from the feces of infected individuals are ingested by susceptible hosts via contaminated hands, food, or water sources. This mode of spread is facilitated by the virus's low infectious dose, requiring as few as fewer than 100 viral particles to establish infection in humans. Direct person-to-person contact, particularly in close-knit settings like households, contributes significantly to transmission, with secondary attack rates among household contacts ranging from 28% to 65% depending on age and vaccination status.^[11]^[62] Fomite-mediated transmission plays a key role in environments with high contact, such as daycare centers, where the virus contaminates surfaces like toys, faucets, and changing tables through fecal residue. Rotavirus exhibits considerable environmental stability, remaining infectious on dry surfaces for weeks to months under typical conditions, which prolongs the risk of indirect spread if surfaces are not properly disinfected. This durability enhances fomite transmission in communal settings, where young children frequently share objects and have poor hygiene practices.^[63]^[64]^[4] Although the fecal-oral pathway dominates, respiratory transmission via aerosolized droplets has been hypothesized based on observations of short incubation periods and rapid outbreaks, but evidence remains limited and debated, with most studies attributing spread to gastrointestinal routes. Outbreaks are common in institutional settings like hospitals and daycares, where close proximity and shared facilities amplify transmission; for instance, European surveillance networks have documented hospital clusters linked to rotavirus in recent seasons, underscoring the need for infection control measures in such environments.^[64]^[65]^[66]

Disease mechanisms

Rotavirus primarily infects the mature enterocytes on the tips of the small intestinal villi, leading to cell lysis and subsequent histopathological changes that underlie the disease process. The virus's non-structural protein NSP4 functions as an enterotoxin, which is secreted from infected cells and binds to specific receptors on neighboring uninfected enterocytes, such as integrins. This interaction mobilizes intracellular calcium stores, activating a signaling cascade that disrupts tight junctions between enterocytes and induces chloride secretion into the intestinal lumen, resulting in watery diarrhea. NSP4 also reorganizes the actin cytoskeleton and impairs the localization of tight junction proteins like ZO-1, further compromising the intestinal barrier.^[67]^[68]^[69] Infection triggers extensive damage to the villus epithelium, causing villus atrophy through accelerated enterocyte loss and reduced absorptive surface area, while stimulating crypt hyperplasia as a compensatory response with increased stem cell proliferation. These changes impair nutrient and fluid absorption, contributing to malabsorption and dehydration. The pathology is confined to the small intestine, with no typical systemic viral spread in immunocompetent hosts, though the breached gut barrier can facilitate bacterial translocation. Recent research (as of October 2025) has identified a key enzyme that enables rotavirus to infect intestinal cells; disabling this enzyme prevented infection in experimental models, highlighting a potential target for antiviral interventions.^[70]^[71]^[64]^[72]^[73] The severity of rotavirus disease exhibits age-dependent patterns, with neonates often protected by passively transferred maternal antibodies that neutralize the virus and mitigate infection. Disease incidence and severity peak around the time of weaning, typically between 4 to 6 months of age in humans, as maternal antibody levels wane and exposure opportunities increase. Secondary bacterial infections can exacerbate diarrhea and complications due to the disrupted epithelial barrier allowing bacterial overgrowth and translocation, though rotavirus itself rarely causes viremia or extraintestinal replication.^[74]^[75]^[76]^[64]

Host immune responses

The innate immune response to rotavirus infection primarily involves recognition of viral double-stranded RNA by pattern recognition receptors in intestinal enterocytes, such as Toll-like receptor 3 (TLR3), which triggers type I interferon production and antiviral signaling.^[77] However, rotavirus employs nonstructural protein 1 (NSP1) to counteract this by mediating the ubiquitin-proteasome degradation of interferon regulatory factors (IRFs), including IRF3, IRF5, IRF7, and IRF9, thereby blocking interferon induction and facilitating viral replication. This antagonism allows rotavirus to evade early innate defenses, though residual interferon responses can limit viral spread in some cell types.^[78] Adaptive immunity against rotavirus is dominated by secretory immunoglobulin A (sIgA) antibodies in the gut mucosa, which neutralize virus particles and prevent reinfection by targeting structural proteins like VP4 and VP6.^[79] Cytotoxic CD8+ T cells play a key role in clearing infected enterocytes during primary infection, recognizing epitopes on VP4, VP6, and VP7, and achieving near-complete resolution within 1-4 days in mouse models, though their contribution diminishes in long-term protection.^[80] Heterotypic protection, effective against diverse rotavirus strains, is mediated by anti-VP6 sIgA, which provides intracellular neutralization during viral transcytosis rather than luminal exclusion, as demonstrated in polarized epithelial cell assays and mouse challenge studies.^[81] Correlates of protection include serum IgA levels exceeding 20 U/mL, which are associated with reduced risk of severe rotavirus gastroenteritis following natural infection or vaccination, explaining up to 32.7% of protective efficacy in clinical trials.^[82] Homotypic immunity, targeting strain-specific VP7 and VP4, predominates in high-income settings and provides robust short-term protection, whereas heterotypic responses, often VP6-driven, confer broader cross-strain efficacy in low-income cohorts with repeated exposures.^[83] A 2018 study showed that antibiotic-induced dysbiosis can enhance rotavirus vaccine boosting and viral shedding in adults by altering Bacteroidetes and Proteobacteria levels, suggesting microbiota-targeted interventions could improve innate and adaptive outcomes. Recent studies (2024–2025) continue to explore gut microbiome modulation's influence on immune responses to rotavirus, including associations with vaccine efficacy in children.^[84]^[85]

Clinical features

Signs and symptoms

Rotavirus infection typically has an incubation period of 1 to 3 days following exposure.^[86] The illness begins abruptly with profuse watery diarrhea, often involving 10 to 20 episodes per day, accompanied by vomiting and fever ranging from 38 to 39°C in approximately 30 to 40% of cases.^[87]^[74] Dehydration is a prominent feature due to fluid loss from vomiting and diarrhea, manifesting as sunken eyes, dry mucous membranes, and lethargy.^[2]^[88] The acute phase generally lasts 3 to 8 days, with vomiting subsiding after 1 to 2 days while diarrhea persists longer.^[2]^[74] Asymptomatic infections occur in 20 to 40% of cases, particularly contributing to silent transmission.^[89]^[90] In adults, infections are often mild or asymptomatic, though they may present with milder diarrhea and abdominal discomfort when symptomatic.^[91] Atypical presentations, such as bloody stools, are rare and typically signal underlying complications rather than primary rotavirus effects.^[92]

Complications

Rotavirus infection primarily affects the gastrointestinal tract, but severe cases can lead to life-threatening complications, most notably through profound dehydration. This dehydration arises from profuse watery diarrhea and vomiting, resulting in hypovolemic shock and electrolyte imbalances, including hypokalemia due to substantial potassium loss in stools.^[93]^[94]^[95] In untreated cases, particularly among young children in resource-limited settings, these effects contribute to a mortality rate of approximately 1-2%, with death often occurring from circulatory collapse or secondary infections.^[1]^[96] Extraintestinal manifestations are uncommon but can involve the central nervous system, including rare instances of aseptic meningitis and encephalitis. These neurological complications typically present as acute encephalopathy with seizures or altered mental status, linked to viral dissemination beyond the gut, and occur in a small subset of hospitalized children with severe gastroenteritis.^[97]^[98]^[99] Notably, intussusception—a telescoping of the intestine—has been associated with rotavirus vaccination rather than the infection itself, with post-vaccination risk estimated at 1-6 excess cases per 100,000 doses, primarily within the first week after administration.^[100]^[101] Long-term sequelae include post-infectious lactose intolerance, resulting from damage to the small intestinal mucosa and transient loss of lactase enzyme activity, which can prolong diarrhea and nutrient malabsorption for weeks to months after resolution of acute symptoms.^[102]^[103] In developing regions, repeated or severe rotavirus episodes exacerbate malnutrition, contributing to growth stunting in up to 30% more children with moderate-to-severe diarrhea compared to unaffected peers, through mechanisms like reduced nutrient uptake and increased metabolic demands.^[104]^[105]^[106] Emerging 2025 data highlight potential gaps in understanding how climate change may elevate complication rates, as rising temperatures and altered precipitation patterns facilitate co-infections with pathogens like norovirus or adenovirus, leading to more severe dehydration and prolonged illness in vulnerable populations.^[107]^[108]^[109]

Diagnosis

Laboratory methods

Laboratory confirmation of rotavirus infection primarily relies on detecting viral antigens or nucleic acids in stool samples, with methods varying in sensitivity, speed, and applicability. Antigen detection assays target the highly conserved VP6 inner capsid protein, which is common to group A rotaviruses, the predominant cause of human disease. Enzyme-linked immunosorbent assay (ELISA) is a widely used method that captures VP6 antigens from stool specimens, offering high throughput by processing up to 96 samples at once, though it requires multiple washing steps. ELISA demonstrates sensitivity ranging from 89.2% to 100% and specificity from 90% to 98.9% when optimized with blocking reagents. Latex agglutination tests provide a faster alternative, yielding results in under 15 minutes without needing advanced equipment, and are particularly useful for outbreak investigations in resource-limited settings, though their sensitivity is generally lower than ELISA at approximately 70-90%.^[110] Molecular techniques offer superior sensitivity for detecting low viral loads and enable strain characterization, which is essential for surveillance and understanding rotavirus diversity. Reverse transcription polymerase chain reaction (RT-PCR) serves as the gold standard, amplifying rotavirus RNA from stool to confirm infection and genotype VP7 (G types) and VP4 (P types) for epidemiological tracking; it achieves 90-95% sensitivity and specificity. Next-generation sequencing (NGS), such as using the Illumina MiSeq platform, allows full-genome analysis of all 11 segments, facilitating detection of mixed infections and novel strains, though it demands higher viral loads and specialized infrastructure. These methods surpass antigen tests in detecting asymptomatic or early infections but are more costly and require laboratory expertise.^[110] Electron microscopy (EM) was the initial diagnostic approach, visualizing the characteristic wheel-like virions with their triple-layered capsids in stool samples, and played a key role in rotavirus discovery in the 1970s. While highly specific, EM has sensitivity of about 60-80% and necessitates viral titers exceeding 10^6 particles per milliliter, making it labor-intensive and time-consuming; it is now rarely employed in routine diagnostics, reserved for research or confirmatory purposes where other methods fail.^[110] Serological assays detect rotavirus-specific antibodies in serum or other fluids to assess prior exposure rather than acute infection. Immunoassays for IgM and IgA indicate recent primary infection, while IgG reflects longer-term immunity, but these tests lack utility in acute diagnosis due to prevalent population seropositivity and delayed antibody responses. Sensitivity and specificity vary by assay (typically 70-90%), and they are more valuable for epidemiological studies of immunity than clinical confirmation.^[110]

Clinical detection

Clinical detection of rotavirus infection relies primarily on clinical suspicion based on patient history and physical examination, particularly in young children. Rotavirus most commonly affects children under 5 years of age, with peak incidence during winter months in temperate climates.^[111] A characteristic presentation includes vomiting that precedes watery, non-bloody diarrhea, often accompanied by fever and abdominal pain, lasting 3 to 8 days.^[36] These features raise suspicion, though they are not pathognomonic, as similar symptoms occur with other enteric pathogens.^[112] Rapid point-of-care tests, such as immunochromatographic assays for rotavirus antigen in stool, provide quick bedside diagnosis. These tests typically yield results in 10 to 20 minutes using fecal specimens and demonstrate high specificity exceeding 95%, though sensitivity may vary around 75-90% depending on the assay.^[113] They are particularly useful in resource-limited settings for immediate confirmation without requiring laboratory infrastructure.^[114] Differential diagnosis involves distinguishing rotavirus from bacterial causes like Salmonella, which often present with bloody diarrhea and higher fever, or other viral etiologies such as norovirus, characterized by shorter-duration vomiting-dominant illness without significant dehydration.^[112] Clinical clues, including the absence of blood in stool and the explosive onset of symptoms in unvaccinated toddlers, help narrow possibilities, though overlap necessitates targeted testing when feasible.^[115] According to World Health Organization guidelines, testing for rotavirus is recommended in children presenting with severe dehydration due to acute gastroenteritis to facilitate outbreak surveillance and inform public health responses.^[116] Laboratory confirmation via more sensitive methods may follow if rapid tests are inconclusive.^[1]

Management

Treatment options

The primary treatment for rotavirus infection is supportive care focused on preventing and managing dehydration through oral rehydration solution (ORS), which has been shown to reduce diarrhea-related mortality by up to 93% in children.^[117] For mild to moderate cases, ORS is administered in small, frequent volumes to replace lost fluids and electrolytes, typically using reduced-osmolarity formulations recommended by health authorities.^[111] In severe dehydration, where oral intake is insufficient, intravenous (IV) fluids are required to rapidly restore hydration and electrolyte balance.^[112] Antiemetic medications, such as ondansetron, can be used to control vomiting in children older than 6 months, facilitating successful oral rehydration by reducing emesis episodes and the need for IV therapy.^[118] A single dose of oral ondansetron has been associated with shorter symptom duration and fewer hospitalizations in randomized trials.^[119] However, antimotility agents like loperamide should be avoided in children, as they can prolong illness and increase the risk of complications by delaying pathogen clearance.^[92] No specific antiviral therapies are approved or routinely effective against rotavirus, as the infection is self-limited in immunocompetent individuals.^[2] Nitazoxanide, an antiparasitic agent with broad-spectrum antiviral activity, has demonstrated limited efficacy in small clinical trials by shortening the duration of diarrhea by approximately 1-2 days compared to placebo, but it is not considered a standard treatment due to inconsistent results across studies and lack of widespread adoption.^[120] Hospitalization is indicated for patients unable to maintain oral intake, exhibiting signs of severe dehydration such as lethargy or sunken eyes, or in shock, where close monitoring and IV support are essential to prevent life-threatening complications like electrolyte imbalances.^[121]

Prognosis

With appropriate rehydration therapy, the prognosis for rotavirus infection is excellent, with most children achieving full recovery within 5 to 8 days.^[2]^[122] Oral rehydration solutions effectively prevent severe dehydration in over 95% of cases when administered promptly, particularly in settings with access to medical care.^[36] Reinfections are common throughout life due to incomplete immunity from prior episodes, but subsequent infections are typically milder, with reduced severity attributed to increasing heterologous immunity across serotypes.^[2]^[123] Certain factors worsen outcomes and elevate the risk of severe disease. Infants under 6 months of age face heightened vulnerability to dehydration and hospitalization, accounting for about 17% of rotavirus-related admissions despite representing a smaller proportion of cases.^[124] Malnutrition and underlying comorbidities, such as immunodeficiency, further increase the risk of hospitalization, exacerbating fluid loss and prolonging recovery.^[112] Repeated rotavirus infections contribute to long-term sequelae, including impaired linear growth and stunting in young children, particularly in low-resource settings where recurrent diarrhea disrupts nutrient absorption.^[125] Vaccination programs have induced herd immunity, reducing transmission and severe outcomes in unvaccinated populations by up to 50% in some regions.^[126] Globally, rotavirus mortality in children under 5 years has declined from an estimated 317,000 deaths in 2000 to 108,000 in 2021 (a 66% decline), largely due to widespread oral rehydration therapy and vaccine introduction, with global vaccine coverage reaching about 55% as of 2023.^[127]^[128]

Prevention

Vaccination strategies

Vaccination against rotavirus primarily involves live attenuated oral vaccines administered to infants to prevent severe gastroenteritis. The two most widely used vaccines are Rotarix, a monovalent vaccine based on a human G1P^[4] strain, and RotaTeq, a pentavalent vaccine composed of bovine-human reassortant strains covering G1, G2, G3, G4, and P^[4] serotypes.^[126]^[129] Rotarix is given in two doses at 2 and 4 months of age, while RotaTeq requires three doses at 2, 4, and 6 months, with the first dose ideally before 15 weeks of age and completion before 8 months.^[129] These vaccines demonstrate high efficacy of 70-90% against severe rotavirus disease in high-income settings, reducing hospitalizations and dehydration requiring medical intervention.^[126]^[130] In low- and middle-income countries, efficacy against severe disease is lower, around 50-64%, attributed to factors such as higher burden of wild-type strains, malnutrition, and gut microbiome interference.^[126]^[131] Despite this, the vaccines significantly lower overall mortality and severe case incidence in these regions due to the high prevalence of rotavirus.^[126] Safety profiles for both Rotarix and RotaTeq are favorable, with the primary concern being a small increased risk of intussusception, estimated at 1-6 cases per 100,000 vaccinated infants, primarily after the first dose.^[132]^[126] The World Health Organization has prequalified these vaccines, along with two Indian-developed options—Rotavac (a monovalent bovine-human reassortant G9P^[133] strain 116E, approved in India in 2014 and WHO-prequalified in 2018) and Rotasiil (a pentavalent bovine-human reassortant covering G1, G2, G3, G4, and G9)—facilitating global procurement and use in national immunization programs.^[126]^[134]^[135] Rotavac and Rotasiil, produced affordably in India, have been integrated into the country's Universal Immunization Programme since 2016, with post-introduction evaluations in 2022 confirming effective implementation and coverage.^[136] Ongoing research as of 2025 includes clinical trials for novel delivery methods, such as dissolvable microneedle patches, to improve accessibility in low-resource settings.^[137]

Hygiene and public health measures

Handwashing with soap and water is a cornerstone of rotavirus prevention, as the virus spreads primarily through the fecal-oral route via contaminated hands. Studies have shown that regular handwashing with soap can reduce the risk of diarrheal diseases, including those caused by rotavirus, by 42-47% in community settings. ^[138] In laboratory tests, handwashing with plain soap reduces rotavirus titers on hands by approximately 72.5%, significantly lowering transmission potential. ^[139] This practice is particularly emphasized after using the toilet, changing diapers, or before preparing food, with guidelines recommending at least 20 seconds of thorough rubbing to maximize efficacy. ^[140] Sanitation improvements play a vital role in endemic areas where rotavirus infection rates are high among young children. Enhanced access to improved sanitation facilities, such as latrines and sewage systems, helps interrupt fecal contamination of the environment, reducing overall disease burden in low-resource settings. ^[141] However, while these measures contribute to broader diarrheal disease control, their standalone impact on rotavirus is modest compared to integrated approaches, as the virus persists in areas with suboptimal hygiene. ^[142] Water treatment methods vary in effectiveness against rotavirus, which exhibits resistance to standard chlorination. Free chlorine disinfection at typical drinking water concentrations is often inadequate for complete inactivation, requiring higher doses or longer contact times that may not be feasible in routine treatment. ^[143] In contrast, boiling water effectively kills rotavirus by denaturing its proteins, providing a reliable option in household settings for reducing waterborne transmission. ^[144] Ultraviolet (UV) irradiation is also highly effective, achieving near-complete inactivation at doses used in modern water purification systems. ^[145] Food hygiene practices complement these efforts by preventing cross-contamination; thorough washing of produce, cooking foods adequately, and avoiding raw or undercooked items minimize the risk of ingesting the virus from contaminated sources. ^[146] During outbreaks, isolation strategies are essential to contain spread in high-risk settings like daycares and hospitals. In childcare facilities, temporary closures or exclusion of symptomatic children for at least 48 hours after symptoms resolve can limit transmission, as demonstrated in post-vaccine era outbreaks where such measures curbed further cases. ^[147] In hospital environments, cohort nursing—assigning dedicated staff to care for infected patients separately—prevents cross-infection, alongside enhanced environmental cleaning with disinfectants effective against non-enveloped viruses. ^[148] Recent global health initiatives highlight ongoing gaps in infrastructure resilience, particularly in the context of climate change exacerbating rotavirus transmission through disrupted water and sanitation systems. The World Health Organization's General Programme of Work for 2025-2028 prioritizes integrating climate adaptation into water, sanitation, and hygiene (WASH) strategies to build resilient systems in vulnerable regions. ^[149] In 2024, WHO and UNICEF initiated reviews of indicators for monitoring climate-resilient WASH, emphasizing investments in durable infrastructure to sustain hygiene measures amid extreme weather events that increase diarrheal risks. ^[150]

History

Discovery

Rotavirus was first identified in 1973 by Australian researchers Ruth Bishop, Geoffrey Davidson, Ian Holmes, and Brian Ruck at the Royal Children's Hospital in Melbourne. They examined duodenal biopsies from children hospitalized with acute, non-bacterial gastroenteritis using electron microscopy and observed abundant virus-like particles in the cytoplasm of mature epithelial cells lining the small intestine. These particles, approximately 70 nanometers in diameter, were distinct from known enteric viruses and marked the initial visualization of what would become recognized as the primary cause of severe childhood diarrhea.^[151] In 1974, British virologist Thomas Henry Flewett proposed the name "rotavirus" for the newly discovered pathogen, derived from the Latin word rota meaning "wheel," due to its characteristic wheel-like morphology observed under electron microscopy. This naming reflected the virus's double-layered capsid structure, which resembled spokes radiating from a hub. By the 1980s, serological and genetic analyses confirmed that group A rotaviruses were the predominant strains infecting humans and animals, responsible for most clinical cases of gastroenteritis. Early epidemiological studies in the late 1970s and 1980s rapidly established rotavirus as a major global pathogen, causing 40-50% of severe acute diarrhea cases in children under five years old in both developed and developing countries.^[151] Estimates from the 1980s indicated that rotavirus led to approximately 500,000 to 1 million deaths annually among young children, primarily from dehydration in resource-limited settings.^[1] Prior to 2000, no effective vaccines were available, leaving management reliant on supportive care such as oral rehydration solutions (ORS) to prevent fatal dehydration, though access to ORS remained limited in many areas.

Vaccine development

The development of rotavirus vaccines accelerated in the 1990s after the virus's role in severe pediatric diarrhea was established. The first licensed vaccine, RotaShield—a live, oral, tetravalent rhesus rotavirus-based formulation—was approved by the U.S. Food and Drug Administration in August 1998 for routine infant immunization. However, within a year, post-marketing surveillance identified a rare but increased risk of intussusception, a form of bowel obstruction, prompting its voluntary withdrawal by the manufacturer in October 1999. Building on lessons from RotaShield, second-generation vaccines emphasized safety and efficacy across diverse populations. Rotarix, a monovalent live attenuated vaccine derived from a human rotavirus strain (G1P^[4]), completed pivotal phase III trials in 2004, demonstrating 85-96% efficacy against severe rotavirus gastroenteritis, and received initial licensure in Mexico that year, followed by approvals in Europe and the United States in 2006. Concurrently, RotaTeq, a pentavalent vaccine comprising five reassortant strains (four human-rotavirus and one bovine-rotavirus), was licensed in the U.S. in February 2006 after a large-scale efficacy trial showed 98% protection against severe disease and no increased intussusception risk.^[152] These vaccines marked a turning point, shifting focus from rhesus-based to human and human-animal hybrid platforms. A key challenge in vaccine design has been the antigenic diversity of rotavirus strains, with over 35 G and P genotype combinations circulating globally, necessitating multivalent formulations like RotaTeq to elicit broader cross-protection against heterotypic strains. The World Health Organization's Strategic Advisory Group of Experts endorsed routine rotavirus vaccination in all national immunization programs in 2009, based on data confirming safety and efficacy in low- and middle-income settings, which spurred global introduction supported by GAVI, the Vaccine Alliance, beginning that year in eligible countries. By 2023, rotavirus vaccine coverage among infants had achieved 55% worldwide.^[153] By early 2025, over 1 billion doses of Rotarix had been supplied globally, averting more than 239,000 deaths from rotavirus gastroenteritis.^[32] Ongoing innovation addresses limitations of live oral vaccines, such as reduced efficacy in low-resource settings due to gut microbiota interference. From 2023 to 2025, mRNA-based candidates have entered early development, including a trivalent VP8* nanoparticle formulation that induced robust neutralizing antibodies and protection in preclinical mouse models, positioning it as a potential parenteral alternative following promising preclinical results in animal models.^[154]

References

[1]
Chapter 19: Rotavirus | Pink Book - CDC
Apr 25, 2024 · Rotavirus is a double-stranded RNA virus of the family Reoviridae. The virus is composed of three concentric shells that enclose 11 gene segments.Missing: overview | Show results with:overview
[2]
About Rotavirus - CDC
Apr 22, 2024 · Rotavirus causes common symptoms like watery diarrhea and vomiting, especially in children. There is no specific medicine to treat rotavirus infection.
[3]
Rotavirus - World Health Organization (WHO)
Rotaviruses are the most common cause of severe diarrhoeal disease in infants and young children worldwide.
[4]
Global Review of the Age Distribution of Rotavirus Disease in ...
Rotavirus gastroenteritis (RVGE) is estimated to cause approximately 200 000 child deaths each year [1]. More than half of the countries in the world now ...Abstract · Methods · Results
[5]
Immunization coverage - World Health Organization (WHO)
Jul 15, 2025 · Rotavirus vaccine was introduced in 131 countries by the end of 2024. Global coverage was estimated at 59%.
[6]
ICTV Virus Taxonomy Profile: Sedoreoviridae 2022
### Taxonomic Classification and Species of Rotavirus
[7]
Chapter 13: Rotavirus | Manual for the Surveillance of Vaccine ...
Jan 8, 2025 · During the pre-rotavirus vaccine era, an estimated 410,000 physician visits, 205-272,000 ED visits, and 55,000–70,000 hospitalizations were ...
[8]
Rotavirus A: Infectious substances pathogen safety data sheet
Oct 21, 2024 · Rotaviruses are classified into one of nine groups (A-I); group I being the most recent addition, and group J has recently been proposed for ...
[9]
Rotavirus A Genome Segments Show Distinct Segregation and ...
Reassortment of the Rotavirus A (RVA) 11-segment dsRNA genome may generate new genome constellations that allow RVA to expand its host range or evade immune ...
[10]
One Year Survey of Human Rotavirus Strains Suggests the ... - NIH
The approximately 10% relative frequency of G12P[6] strains detected in this study suggests that this strain is emerging in Cameroon and should be monitored ...
[11]
14 years of rotavirus A surveillance: unusual dominance of equine ...
Post-pandemic data show an unusually strong dominance of the equine-like G3P[8] genotype which carried a DS-1-like genotype constellation in the period 2021 to ...
[12]
Rotavirus infection | Nature Reviews Disease Primers
Nov 9, 2017 · Rotaviruses are non-enveloped double-stranded RNA (dsRNA) viruses that have a complex architecture of three concentric capsids that surround a ...
[13]
Rotavirus gene structure and function - PMC - NIH
Knowledge of the structure and function of the genes and proteins of the rotaviruses has expanded rapidly. Information obtained in the last 5 years has revealed ...
[14]
Human rotavirus - Pathogen Safety Data Sheets - Canada.ca
It is also susceptible to heating above 50 °C (for 30 minutes), but is stabilized in 2M magnesium sulphate. SURVIVAL OUTSIDE HOST: HRV can survive ambient ...
[15]
Genus: Rotavirus | ICTV
Rotaviruses are currently grouped into nine species (Rotavirus A, Rotavirus B, Rotavirus C, Rotavirus D, Rotavirus F, Rotavirus G, Rotavirus H, Rotavirus I and ...Missing: AH | Show results with:AH
[16]
Rotavirus non-structural proteins: Structure and Function - PMC
This brief review highlights our current knowledge of the structure-function relationships of the rotavirus non-structural proteins, well as fascinating ...
[17]
Rotavirus contains integrin ligand sequences and a disintegrin-like ...
The spike viral protein VP4 and major outer capsid glycoprotein VP7 independently elicit neutralizing, protective antibodies and are determinants of virulence.
[18]
Antibodies to Rotavirus Outer Capsid Glycoprotein VP7 Neutralize ...
Both VP4 and VP7 induce neutralizing and protective antibodies. To gain insight into the virus neutralization mechanisms, the effects of neutralizing monoclonal ...<|control11|><|separator|>
[19]
Rotaviruses - ScienceDirect.com
Sep 22, 2014 · Structure and structure–function studies of rotavirus particles and proteins. •. Rotavirus classification and evolution based on whole genome ...
[20]
https://ictv.global/report/chapter/sedoreoviridae/sedoreoviridae/rotavirus
[21]
https://pmc.ncbi.nlm.nih.gov/articles/PMC3422752/
[22]
Global, Regional, and National Estimates of Rotavirus Mortality in ...
Apr 7, 2016 · We estimated that the number of rotavirus deaths in children <5 years of age declined from 528 000 (range, 465 000–591 000) in 2000 to 215 000 (rangeMissing: era | Show results with:era
[23]
Full article: Impact of rotavirus vaccination on diarrheal disease ...
May 31, 2024 · Rotarix and RotaTeq rotavirus vaccines have been proven to be safe and effective in preventing rotavirus illness. About 9 out of 10 children who ...
[24]
Global impact of rotavirus vaccination on diarrhea hospitalizations ...
Data from the WHO-coordinated Global Rotavirus Surveillance Network reported a 40% relative decline in rotavirus positive specimens among children <5 years old ...
[25]
Disease burden of rotavirus related diarrhea in children under 5 ...
May 8, 2025 · Rotavirus (RV), a highly contagious pathogen, is responsible for severe pediatric diarrhea, accounting for approximately 128,500 deaths ...Search Strategy And... · Results · Rv Positivity Rates
[26]
Assessing the Global Burden of Rotavirus-Induced Diarrheal Diseases
In 2021, ~170 000 deaths globally were attributed to rotavirus-induced diarrheal diseases. While the global burden has significantly declined since 1990, ...
[27]
Two decades of GSK rotavirus vaccine (RV1): a global analysis to ...
Results. Approximately 431 million children under 5 years received a complete RV1 course from 2004 to 2023, avoiding over 220,000 RVGE-related deaths globally.1. Introduction · 3. Results · 4. Discussion<|control11|><|separator|>
[28]
Seasonality of rotavirus disease in the tropics: a systematic review ...
We conclude that rotavirus responds to changes in climate in the tropics, with the highest number of infections found at the colder and drier times of the year.
[29]
Global Seasonality of Rotavirus Disease - PMC - PubMed Central
Observations from several countries challenged the traditional dogma that rotavirus disease is seasonal in temperate settings but not in tropical countries. We ...
[30]
WHO Immunization Data portal - All Data
Number of cases enrolled in GRSN and tested for rotavirus by country and by year since 2008 (as reported to WHO as of July 2024).
[31]
Rotavirus | Pediatrics In Review - AAP Publications
Oct 1, 2023 · Rotavirus is the most common cause of severe gastroenteritis in children younger than 5 years, accounting for significant morbidity and mortality in this age ...
[32]
Disease and epidemiology - WHO EMRO
Rotavirus gastroenteritis is caused by rotavirus that infects the stomach and bowel. Rotavirus gastroenteritis is common in infants and young children.
[33]
Diarrhoeal disease - World Health Organization (WHO)
Mar 7, 2024 · Rotavirus and E. coli are the most common pathogens among children across all age groups, while parasitic pathogens, are prevalent in children ...Overview · Causes · Prevention And Treatment<|control11|><|separator|>
[34]
Rotavirus infection and the current status of rotavirus vaccines
Globally, infection results in more than 600,000 deaths each year in children less than 5 years old who die from severe dehydration and electrolyte and acid- ...Review Article · Clinical Illness · Disease Burden
[35]
Cost-effectiveness Analysis of a Rotavirus Immunization Program for ...
May 6, 1998 · We estimate the full cost of rotavirus disease in the United States to be $1 billion, of which $264 million is attributable to medical costs.Missing: pre- | Show results with:pre-
[36]
[PDF] Economic Costs of Rotavirus Disease and the Value of Vaccines
(37) With an average cost of nearly €2,000 per hospitalization and €350 per outpatient hospital visit, the health care system saved, on average, an estimated € ...Missing: $1 billion
[37]
[PDF] Rotavirus Vaccine Introduction and Coverage
A review of sever- al studies found an excess risk of intussusception of 1–5 per 100,000 infants vaccinated in some set- tings, while it found no increased risk ...
[38]
Review of group A rotavirus strains reported in swine and cattle - PMC
Group A rotavirus (RVA) infections cause severe economic losses in intensively reared livestock animals, particularly in herds of swine and cattle.
[39]
Rotavirus in Animals - News-Medical
The rotavirus strains classified into serogroups A, B, and C are pathogenic for humans and various animal species. The most virulent and commonly isolated ...
[40]
Rotavirus Infections of Poultry - Merck Veterinary Manual
Four groups of rotavirus infect avian species and are designated as A (RVA), D (RVD), F (RVF), and G (RVG), based on genetic or serological characterization.
[41]
Group A rotavirus gastroenteritis: post-vaccine era, genotypes and ...
Group B rotavirus was detected in humans, cattle, sheep, pigs, does and rats. Group C rotavirus infects pigs, humans, cattle, dogs and ferrets.
[42]
Porcine rotavirus continues to plague the global pig industry
Feb 5, 2025 · ... Groups A and C are present [4]. Group C is more common in nursing pigs that are 1–10 days old. It is commonly found in contaminated ...
[43]
rotavirus infections in livestock and poultry | CABI Compendium
Nov 21, 2019 · These have been classified into 7 groups (A-G) and 4 serotypes. Groups A, B, and C have been found in both humans and animals while groups D, E, ...
[44]
Rotavirus in Calves and Its Zoonotic Importance - PMC
Rotavirus is a major pathogen responsible for diarrheal disease in calves, resulting in loss of productivity and economy of farmers.
[45]
Diarrhea in Neonatal Ruminants - Digestive System
Neonatal diarrhea in ruminants remains the most important cause of death in calves under one month of age. Various bacterial, viral, and protozoal agents ...
[46]
NC_old1202: Enteric Diseases of Food Animals - NIMSS
Infections are common and estimates of annual economic losses are ~$100 million for the US swine industry. ... economic losses to the dairy and cattle industries.
[47]
Diarrhea (Scours) in Small Ruminants - U.OSU
Jun 11, 2019 · Rotavirus generally causes diarrhea in lambs and kids at 2-14 days of age. Young animals become very depressed and dehydrated. Rotavirus is ...
[48]
Rotavirus strains in neglected animal species including lambs, goats ...
Diarrhea in lambs is a complex, multi-factorial disease including animal susceptibility, nutritional status, environmental factors, and a variety of infectious ...
[49]
Identification by Full-Genome Analysis of a Bovine Rotavirus ...
To date, no report has provided evidence for the direct transmission of the most common G6P[1], G6P[5], or G6P[11] bovine rotavirus strains to human children.
[50]
Origin of rare bovine rotavirus strains detected from Japanese children
RV infects not only humans but also various young domestic and wild animals, such as monkeys, bovine, pigs, horses, dogs, cats, rats, chicken and deer [3-6].
[51]
Whole genome sequence analysis of bovine G6P[11] rotavirus strain ...
It was suggested already that the zoonotic transmission of G6 occurs probably from cattle or other ungulates (Bányai et al., 2009, Matthijnssens et al., 2009).
[52]
Zoonotic bovine rotavirus strain in a diarrheic child, Nicaragua
Aug 6, 2025 · Bovine G6 strains were reported in many countries to be associated with P [1], P [5], and P [11] (11,12,(14)(15)(16). Two G8P [1] strains ...
[53]
Diversity and Potential Cross-Species Transmission of Rotavirus A ...
Jan 13, 2025 · A total of 24 samples, originating from wild boars, rodents, bats, and birds tested positive for RVA. Next generation sequencing and ...
[54]
Unusual G3P[10] bat‐like rotavirus strains detected in children with ...
Oct 17, 2024 · The results of this study supported the roles of interspecies transmission of RVA strains among bats and humans in the natural environment.
[55]
At Least Seven Distinct Rotavirus Genotype Constellations in Bats ...
At least 7 distinct bat RVA genotype constellations (GCs) were identified, which included evidence of reassortments and 6 novel genotypes.
[56]
Community burden and transmission of acute gastroenteritis caused ...
Secondary attack rates were 15% (37 of 244 participants) for norovirus and 28% (33 of 120 participants) for rotavirus and asymptomatic transmission rates were ...
[57]
Prevalence of rotavirus on high-risk fomites in day-care facilities
Conclusions: Moist surfaces including the telephone, water fountains, and water-play tables are common sources of rotavirus contamination within the day-care ...Missing: stability | Show results with:stability
[58]
Rotaviruses: From Pathogenesis to Disease Control—A Critical ...
Rotavirus is a ubiquitous and vastly stable organism that may persist in the environment for weeks or months without losing infectivity if not disinfected [35].
[59]
Contribution of the EuroRotaNet surveillance network to rotavirus ...
Sep 25, 2025 · The EuroRotaNet surveillance network has generated one of the largest datasets of rotavirus genotypes globally. The use of standardised typing ...
[60]
National norovirus and rotavirus report, week 2 report - GOV.UK
Dec 29, 2024 · Outbreaks in hospital settings Up to week 52 of the 2024/2025 season, 153 outbreaks have been reported to HNORS (Figure 3), 11.7% higher than ...Missing: institutional clusters
[61]
The rotavirus enterotoxin NSP4 mobilizes intracellular calcium ... - NIH
The rotavirus nonstructural protein NSP4 acts as a viral enterotoxin to induce diarrhea and causes Ca2+-dependent transepithelial Cl− secretion in young mice.
[62]
NSP4 Enterotoxin of Rotavirus Induces Paracellular Leakage ... - NIH
In summary, our results indicate that NSP4 specifically perturbs the paracellular pathway, reorganizes F-actin, and prevents transport of the ZO-1 protein to ...
[63]
Rotavirus NSP4 is secreted from infected cells as an oligomeric ...
Dec 20, 2011 · Nonstructural glycoprotein 4 (NSP4) encoded by rotavirus is the only viral protein currently believed to function as an enterotoxin.Measurement Of Nsp4 Binding... · Secreted Nsp4 Forms... · Nsp4 Binds To...
[64]
Rotaviruses, Noroviruses, and Other Gastrointestinal Viruses - PMC
Rotaviruses replicate in the villus tip cells of the small bowel, where the pathologic process includes shortening and atrophy of the villi, mononuclear ...
[65]
Intestine Villus Atrophy - an overview | ScienceDirect Topics
Rotaviruses infect the mature enterocytes on the tips of small intestinal villi, leading to villous atrophy with secondary hyperplasia of the crypts. It has ...Diarrhea · 82.5. 1 Inflammatory... · Complications<|control11|><|separator|>
[66]
Rotaviruses: from pathogenesis to vaccination - PMC
Although there are many case reports associating rotavirus with many systemic illnesses, there is no proof of causation from extraintestinal spread of rotavirus ...
[67]
Rotavirus Gastroenteritis: Diagnosis, Management, & Prevention
Aug 30, 2025 · The infectious dose of rotavirus is estimated to be 100–1000 viral particles. Transmission of rotavirus occurs mainly through the fecal-oral ...
[68]
Literature Review on Rotavirus: Disease and Vaccine Characteristics
Cohort studies report the highest infection rate between 4 to 6 months of age, coinciding with weaning, declining maternal antibody or increased opportunity for ...Results · 1.3. Epidemiology Of The... · 2. Rv Vaccine, Rotateqtm
[69]
Acute effects of rotavirus and malnutrition on intestinal barrier ... - NIH
... bacterial translocation with subsequent enteritis and diarrhea[8]. Moreover ... rotavirus infectivity in cell culture models of rotavirus infection[16].
[70]
Age-Dependent TLR3 Expression of the Intestinal Epithelium ...
May 3, 2012 · Here we investigated age-dependent mechanisms of the intestinal epithelial innate immune response to rotavirus infection in an oral mouse ...
[71]
Re-Examining Rotavirus Innate Immune Evasion - NIH
Jun 14, 2022 · Rotavirus nonstructural protein 1 subverts innate immune response by inducing degradation of IFN regulatory factor 3. ... Rotavirus NSP1 inhibits ...Missing: blockade | Show results with:blockade
[72]
Immune Responses to Rotavirus Infection and Vaccination ... - NIH
Only high titers of RV-specific copro-IgA antibodies are correlated with protection. Most intestinal IgA antibodies appear to be directed against VP6 (ie, they ...Humoral Immune Responses · Cellular Immune Responses · Humoral Immunity
[73]
CD8+ T cells can mediate almost complete short-term and ... - PubMed
... CD8+ T cells have a 1- to 4-day delay in clearance of primary rotavirus infection. A role for CD8+ T cells in protection from reinfection with rotavirus was ...
[74]
Rotavirus Anti-VP6 Secretory Immunoglobulin A Contributes to ... - NIH
Heterotypic protection observed after rotavirus infection can involve several mechanisms. Using a specific anti-VP6 IgA (IgA7D9), we show that intracellular ...Missing: adaptive | Show results with:adaptive
[75]
Association of serum anti-rotavirus immunoglobulin A antibody ...
In the RV1 vaccine group, anti-RV-IgA antibody concentrations ≥20 U/mL appear to be associated with a reduced risk of both any and severe RVGE. In the placebo ...
[76]
Correlates of protection against human rotavirus disease and the ...
Dec 3, 2014 · High levels of anti-VP6 antibodies are detected in humans following infection and vaccination and may confer heterotypic protection (see also ...Article · Protection Induced By... · Correlates Of Homotypic And...
[77]
Effect of Antibiotic-Mediated Microbiome Modulation on Rotavirus ...
This study suggests that targeted modulation of the intestinal microbiota alters both RVV boosting and shedding in healthy adults.
[78]
Rotavirus infection - Knowledge @ AMBOSS
Apr 19, 2023 · Incubation period: 1–3 days · Fever, malaise · Abdominal pain · Vomiting and watery diarrhea. Can be severe: > 10 loose, watery stools within 24 ...
[79]
Rotavirus infection in adults - The Lancet Infectious Diseases
The diarrhoea may be profuse, and 10–20 bowel movements per day are common. When examined, the stool from affected patients is generally devoid of faecal ...
[80]
Rotavirus - Symptoms & causes - Mayo Clinic
Aug 18, 2025 · In adults, rotavirus infection doesn't tend to causes symptoms or causes mild symptoms. In children and others, symptoms often start within two ...Overview · When To See A Doctor · Prevention
[81]
ASYMPTOMATIC ENDEMIC ROTAVIRUS INFECTIONS IN THE ...
A significant proportion (20–40%) of infections are asymptomatic, which contributes to the spread of the virus and might reduce the efficiency of prevention ...
[82]
Nosocomial rotavirus gastroenterocolitis in a large tertiary paediatric ...
... infection spread [5, 6]. Asymptomatic rotavirus infection (present in 20-40% of cases) is a particular cause of concern. Patients and health care workers ...
[83]
Rotavirus | Johns Hopkins ABX Guide
Mar 18, 2023 · Incubation period: 2 days; Easily spread among infants and younger ... Most rotavirus infections in adults are asymptomatic. Rotavirus ...
[84]
Rotavirus Gastroenteritis - Gastrointestinal Disorders - Merck Manuals
Rotavirus is the most common cause of sporadic, severe, dehydrating diarrhea in young children worldwide (peak incidence, age 3 to 15 months).General References · Symptoms And Signs Reference · Treatment References
[85]
Severity of rotavirus gastroenteritis in an Indian population
Aug 11, 2014 · Severe dehydration, leading to acute shock with electrolyte imbalance is believed to be the major cause of death in rotavirus gastroenteritis ( ...
[86]
[PDF] The Epidemiology and Disease Burden of Rotavirus
India accounted for approximately 16% of global rotavirus deaths in children under 5 in 2017 but has since fully in- troduced rotavirus vaccines in their ...
[87]
Overview of Gastroenteritis - Digestive Disorders - Merck Manuals
Excessive vomiting or diarrhea can result in electrolyte problems such as low levels of potassium in the blood (hypokalemia) and dehydration, which can cause ...Causes Of Gastroenteritis · Bacteria · Treatment Of Gastroenteritis
[88]
Rotavirus the Leading Cause of Diarrheal Deaths Among Children ...
Apr 30, 2024 · Rotavirus as the leading cause of death from diarrhea in children under 5 years of age, globally. Using data from 2000 up to 2021, researchers estimated that ...
[89]
Rotavirus infection-associated central nervous system complications
While many studies have conclusively shown that rotavirus infection causes gastroenteritis and is associated with various extraintestinal manifestations ...
[90]
Rotavirus Gastroenteritis and Central Nervous System (CNS) Infection
Neurological complications include meningitis, encephalitis, convulsions, hemorrhagic shock and encephalopathy ... Aseptic meningitis in an infant with rotavirus ...
[91]
Understanding the Central Nervous System Symptoms of Rotavirus
Additionally, there is growing evidence of CNS complications, such as convulsions, encephalitis ... Aseptic meningitis in an infant with rotavirus gastroenteritis ...
[92]
Rotavirus Vaccine and Intussusception - CDC
Jan 27, 2017 · This additional risk is estimated to range from about 1 in 20,000 to 1 in 100,000 US infants who get rotavirus vaccine.
[93]
Intussusception: A Very Rare Risk After Rotavirus Vaccination
Sep 6, 2018 · Rotavirus vaccine is the only medicine associated with the development of intussusception. A low level risk of 1–6 excess cases per 100,000 ...
[94]
Lactose avoidance for young children with acute diarrhoea - PMC
Most trials reported that rotavirus infection was the most commonly identified cause of acute diarrhoea in trial participants. ... Lactose intolerance in ...
[95]
Lactose Intolerance in Infants, Children, and Adolescents | Pediatrics
Sep 1, 2006 · Etiologies include acute infection (eg, rotavirus) causing small intestinal injury with loss of the lactase-containing epithelial cells from the ...Definitions · Diagnosis · Management<|separator|>
[96]
Stunting Following Moderate-to-Severe Diarrhea Among Children ...
Apr 19, 2023 · The association of MSD with subsequent stunting among children aged <5 years in sub-Saharan Africa did not change after rotavirus vaccine ...Methods · Results · Variable Definitions
[97]
Why Rotavirus Vaccine Introduction in Nigeria is a Milestone for ...
By preventing diarrheal disease and the malnutrition that may be associated with rotavirus infection, rotavirus vaccines can reduce the risk of stunting and ...
[98]
Long-term impact of changing childhood malnutrition on rotavirus ...
The reduction of acute childhood malnutrition is significantly associated with increasing rotavirus diarrhoea among under-5 children. Thus mass vaccination in ...
[99]
Climate Change and Its Emerging Impact on Pediatric ...
Aug 31, 2025 · Climate change has intensified these challenges, with rising temperatures, floods, and droughts increasingly influencing disease patterns.
[100]
Predicting the burden of co-infections in seasonally driven dynamics ...
Similarly, co-infections from gastrointestinal diseases, in particular those involving rotavirus and norovirus, can result in severe diarrhea and higher rates ...Missing: complications | Show results with:complications
[101]
Time-series analysis of climatic drivers of pediatric rotavirus and ...
Aug 25, 2025 · Notably, RV positivity in preschool children (3–6 years) jumped after 2021 and peaked in 2024 (28.18%), while AdV rates in groups 1–3 and 3–6 ...Missing: complications | Show results with:complications
[102]
Advances in the Diagnosis and Treatment of Rotavirus Infections
Electron microscopy (EM) was the first method used for the diagnosis of RVs. Since the 1980s, ELISA tests have been commonly used, providing satisfactory ...
[103]
Clinical Overview of Rotavirus - CDC
Apr 2, 2024 · Rotavirus disease is characterized by vomiting and watery diarrhea for three to eight days. Fever and abdominal pain also are common.
[104]
Rotavirus - StatPearls - NCBI Bookshelf
Jan 2, 2023 · Transmission of rotavirus occurs primarily through the fecal-oral route and is frequently passed between individuals in daycare or household ...
[105]
Evaluation of the diagnostic performance of EpiTuub® Fecal ...
Nov 30, 2023 · Fecal Rotavirus Antigen Rapid Test Kit has shown a sensitivity of 75.5% and specificity of 98.2%. The kit was also found to have 89.9% and 95.0% ...
[106]
Bioline Rotavirus | Abbott Point of Care
Early detection of rotavirus antigen group A all serotype · Convenient and clean test · Test result : 10-20min · Specimen : Fecal specimens (about 50mg) · 18 months ...
[107]
Viral Gastroenteritis Differential Diagnoses - Medscape Reference
Jul 25, 2025 · Symptoms may range from mild to severe bloody diarrhea and colitis, with pseudomembranous colitis being the most severe form. Complications ...
[108]
[PDF] Rotavirus - World Health Organization (WHO)
Sep 5, 2018 · Rotavirus, a member of the reovirus family, causes watery diarrhoea, vomiting and severe dehydration in young children. Rotavirus is common ...
[109]
The effect of oral rehydration solution and recommended home ...
We estimated that ORS may prevent 93% of diarrhoea deaths. Conclusions ORS is effective against diarrhoea mortality in home, community and facility settings; ...
[110]
Antiemetics in Children With Acute Gastroenteritis: A Meta-analysis
Apr 1, 2020 · The authors found that ondansetron was the best intervention to reduce vomiting, the need for intravenous rehydration, and hospitalizations.
[111]
Ondansetron treatment reduces rotavirus symptoms-A ... - PubMed
Ondansetron, a serotonin receptor antagonist could attenuate rotavirus- and norovirus-induced vomiting and diarrhoea, which would facilitate oral rehydration.
[112]
Nitazoxanide in Acute Rotavirus Diarrhea: A Randomized Control ...
Oral nitazoxanide was found to be effective and safe in the management of acute rotavirus diarrhea in Indian children.Missing: antivirals | Show results with:antivirals
[113]
Rotavirus Treatment & Management: Prehospital Care, Emergency ...
Sep 28, 2023 · Antiemetics may be considered for children older than 6 months to control emesis. ... The role of oral ondansetron in children with ...Prehospital Care · Emergency Department Care · Further Care
[114]
Rotavirus: Practice Essentials, Background, Pathophysiology
Sep 28, 2023 · Rotavirus is a self-limited infection. Fluid stool losses may be dramatic, and death from dehydration is not uncommon, particularly in developing countries.
[115]
Rotavirus Infection in Infants as Protection against Subsequent ...
Oct 3, 1996 · In infants, natural rotavirus infection confers protection against subsequent infection. This protection increases with each new infection and reduces the ...
[116]
Prevention of Rotavirus Gastroenteritis Among Infants and Children
Aug 11, 2006 · Rotavirus vaccine is contraindicated for infants with a serious allergic reaction to any vaccine component or to a previous dose of vaccine.
[117]
Etiology of diarrheal hospitalizations following rotavirus vaccine ...
Apr 10, 2024 · Malnourished children are at higher risk of mortality and morbidity following diarrheal illness and certain enteropathogens have been associated ...
[118]
Modeling the long-term impacts of enteric infections - Defeat DD
Jun 17, 2021 · Repeated gut infections can have long-term impacts on a child's development. A modeling study sheds light on how these infections cause ...
[119]
Rotavirus Vaccines - World Health Organization (WHO)
WHO continues to recommend that the first dose of rotavirus vaccine be administered as soon as possible after 6 weeks of age, along with DTP vaccination. Apart ...
[120]
Rotavirus Vaccination: For Providers - CDC
RotaTeq® (RV5) has been approved for use since 2006, and is given in three doses at 2 months, 4 months, and 6 months of age. · Rotarix® (RV1) has been approved ...
[121]
Rotavirus Vaccines: Effectiveness, Safety and Future Directions - PMC
Similar to the results from the clinical trials of RotaTeq and Rotarix, ROTAVAC's vaccine efficacy against hospitalization for rotavirus diarrhea was 54% in a ...
[122]
Global estimates of rotavirus vaccine efficacy and effectiveness
Rotavirus is the leading cause of diarrhoea worldwide, particularly affecting young children. While national rotavirus immunization programs have reduced ...
[123]
Rotavirus vaccine safety update - World Health Organization (WHO)
The Committee noted that both RotaTeq® and Rotarix® vaccines had a good safety profile and that although they may be associated with an increased (up to 6 ...
[124]
India-made rotavirus vaccine achieves World Health Organization ...
ROTAVAC was licensed by the Drugs Controller General of India in early 2014. India began a phased introduction of the vaccine in its national immunization ...
[125]
Post-introduction evaluation (PIE) of rotavirus vaccine in India - PMC
Jul 17, 2024 · Rotavirus vaccine (RVV) post-introduction evaluation (PIE) was conducted in March 2022 to assess the implementation process of RVV introduction in India.
[126]
Effect of washing hands with soap on diarrhoea risk in the community
On current evidence, washing hands with soap can reduce the risk of diarrhoeal diseases by 42–47% and interventions to promote handwashing might save a million ...Missing: percentage | Show results with:percentage
[127]
In Vivo Protocol for Testing Efficacy of Hand-Washing Agents
Sep 8, 1989 · The tap water alone and the soap reduced the virus titers by 83.6 and 72.5% and the bacterial titers by 90 and 68.7%, respectively. The results ...
[128]
[PDF] Guideline for Hand Hygiene in Health-Care Settings - CDC
panol and 70% ethanol are more effective than medicated soap or nonmedicated soap in reducing rotavirus titers on fingerpads. (137,138). A more recent study ...
[129]
An Analysis of Childhood Clinic Visits for Diarrhea in Peru, 2005–2015
Improved water/sanitation may operate synergistically with rotavirus vaccination to reduce childhood clinic visits for diarrhea in Peru.
[130]
Cost-effectiveness of Rotavirus vaccination in Vietnam
Jan 21, 2009 · Since rotavirus is endemic in both developed and developing countries, improved hygiene is unlikely to be effective in reducing rates of ...Model · Discussion · Abstract<|separator|>
[131]
Effects of chlorine and chlorine dioxide on human rotavirus infectivity ...
The disinfection efficacy of ClO2 is higher than that of chlorine for HRV. •. The current chlorine treatment strategy is inadequate to manage the risk of ...
[132]
Effects of Boiling Drinking Water on Diarrhea and Pathogen-Specific ...
The evidence suggests that boiling provides measureable health benefits for pathogens whose transmission routes are primarily water based.
[133]
Rotavirus is Inactivated by Germicidal UV-C Light | Ultraviolet.com
Feb 25, 2025 · Germicidal Ultraviolet (UV-C) water disinfection can inactivate Rotavirus in well water, swimming pools and hot tubs, drinking water, and food prep water.
[134]
[DOC] Rotavirus-infection-and-prevention-through-home-hygiene_0.doc
Reducing any rotavirus present on hands is best accomplished by thorough handwashing with running water and plain soap. Washing with plain soap and water ...Missing: 30-50% | Show results with:30-50%
[135]
Three Rotavirus Outbreaks in the Postvaccine Era — California, 2017
Apr 27, 2018 · Rotavirus outbreaks in a child care center and an adult assisted living facility caused primarily mild illness. In a pediatric subacute care facility, illness ...
[136]
[PDF] Recommendations for the Control of Gastroenteritis Outbreaks in ...
Develop outbreak management policies and procedures. • Prevent outbreaks. • Identify and isolate cases to prevent disease spread. • Respond to and manage a ...<|separator|>
[137]
WHO General Programme of Work 2025–2028 prioritizes climate ...
May 28, 2024 · This initiative aims to safeguard health amidst climate challenges, foster synergies between climate adaptation and mitigation efforts, ...Missing: rotavirus infrastructure
[138]
WHO / UNICEF review indicators for climate resilient WASH
Feb 28, 2025 · In 2024, WHO and UNICEF launched a review to identify indicators for enhanced national and global monitoring of climate resilient Water, ...Missing: rotavirus | Show results with:rotavirus
[139]
Discovery of rotavirus: Implications for Child health - Bishop - 2009
Oct 1, 2009 · In 1973 Ruth Bishop, Geoffrey Davidson, Ian Holmes, and Brian Ruck identified abundant particles of a 'new' virus (rotavirus) in the cytoplasm ...Abstract · Introduction · Discovery and importance of... · Other aspects of rotavirus...
[140]
Safety and Efficacy of a Pentavalent Human–Bovine (WC3 ...
Jan 5, 2006 · This vaccine was efficacious in preventing rotavirus gastroenteritis, decreasing severe disease and health care contacts.
[141]
Rotavirus vaccine (RV) supply and demand update - Unicef
Oct 30, 2024 · By the end of 2023, rotavirus vaccine has been introduced in 123 countries, with WHO estimating a vaccination coverage of 55 per cent.
[142]
mRNA-based VP8* nanoparticle vaccines against rotavirus ... - Nature
Dec 22, 2023 · Our data provide evidence that trivalent LS-P2-VP8* represents a promising mRNA-based next-generation rotavirus vaccine candidate.Results · Mrna Vaccines · Vaccination Studies